PDCD1 and frontotemporal dementia: Therefore, this retrospective study aimed to evaluate the efficacy and safety of FTD/TPI plus ramucirumab versus FTD/TPI monotherapy in patients with AGC in later-line treatment, most of whom had a history of anti-PD-1 therapy.